Diagnosis and management of primary hyperparathyroidism - A scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism;Diagnóstico e manejo do hiperparatireoidismo primário - Uma posição científica do Departamento de Metabolismo Ósseo, a Sociedade Brasileira de Endocrinologia e Metabolismo

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 57, Issue 6, 2013, Pages 406-424

  Bandeira, Francisco ^a   Griz, Luiz ^a   Chaves, Narriane ^a   Carvalho, Nara Crispim ^a   Borges, Lívia Maria ^a   Lazaretti Castro, Marise ^b   Borba, Victoria ^c   Castro, Luiz Cláudio de ^d   Borges, João Lindolfo ^e   Bilezikian, John ^f  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d UNIVERSITY OF BRASILIA   (Brazil)

^e UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^f College of Physicians and Surgeons Columbia University ^*  (United States)

Author keywords

Diagnosis; Normocalcemic primary hyperparathyroidism; Parathyroidectomy; Primary hyperparathyroidism; Treatment

Indexed keywords

PARATHYROID HORMONE;

ANIMAL; ARTICLE; BLOOD; EVIDENCE BASED MEDICINE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; PARATHYROID GLAND; PARATHYROIDECTOMY; PATHOLOGY; PRACTICE GUIDELINE; STANDARD;

ANIMALS; EVIDENCE-BASED MEDICINE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; PARATHYROID GLANDS; PARATHYROID HORMONE; PARATHYROIDECTOMY;

EID: 84884199627     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302013000600002     Document Type: Article

References (171)

1. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med. 2005;257:6-17.
2. Bandeira F., Griz L, Caldas G, Bandeira C, Freese E. From mild to severe primary hyperparathyroidism: the Brazilian experience. Arq Bras Endocrinol Metab. 2006;4:657-63.
3. Rodgers SE, Lew JI, Solórzano CC. Primary hyperparathyroidism. Curr Opin Oncol. 2008;20:52-8.
4. Eufrasino CS, Holanda NC, Prazeres PA, Bandeira F. Epidemiology of primary hyperparathyroidism and its nonclassical manisfestations in the city of Recife, Brazil. Endocr Rev. 2012;33:SUN-336.
5. Mayer D. Essential Evidence-Based Medicine. Cambridge: Cambridge University Press; 2004.
6. Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005;132(3):359-72.
7. Brandi ML, Falchetti A. Genetics of primary hyperparathyroidism. Urol Int. 2004;72(Suppl 1):11-6.
8. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658-71.
9. Simonds WF, James-Newton LA, Agarwal SK, Yang B, Skarulis MC, Hendy GN, et al. Familial isolated hyperparathyroidism: clinical and genetic characteristics of thirty-six kindreds. Medicine (Baltimore). 2002;81:1-26.
10. Reh C, Hendy G, Cole DE, Jeandron DD. Neonatal hyperparathyroidism with heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. J Clin Endocrinol Metab. 2011;96:707-12.
11. Tisell LE, Hansson G, Lindberg S, Ragnhult I. Hyperparathyroidism in persons treated with X-rays for tuberculous cervical adenitis. Cancer. 1977;40(2):846-54.
12. McMullen T, Bodie G, Gill A, Ihre-Lundgren C, Shun A, Bergin M, et al. Hyperparathyroidism after irradiation for childhood malignancy. Int J Radiat Oncol Biol Phys. 2009;73(4):1164.
13. Boehm BO, Rosinger S, Belyi D, Dietrich JW. The parathyroid as a target for radiation damage. N Engl J Med. 2011;365(7):676-8.
14. Schneider AB, Gierlowski TC, Shore-Freedman E, Stovall M, Ron E, Lubin J. Dose-response relationships for radiation-induced hyperparathyroidism. J Clin Endocrinol Metab. 1995;80(1):254-7.
15. Tezelman S, Rodriguez JM, Shen W, Siperstein AE, Duh QY, Clark OH. Primary hyperparathyroidism in patients who have received radiation therapy and in patients who have not received radiation therapy. J Am Coll Surg. 1995;180(1):81-7.
16. Wilson SD, Doffek KM, Wang TS, Krzywda EA, Evans DB, Yen TW. Primary hyperparathyroidism with a history of head and neck irradiation: the consequences of associated thyroid tumors. Surgery. 2011;150(4):869-77.
17. Fjälling M, Dackenberg A, Hedman I, Tisell LE. An evaluation of the risk of developing hyperparathyroidism after 131I treatment for thyrotoxicosis. Acta Chir Scand. 1983;149(7):681-6.
18. Hsi ED, Zukerberg LR, Yang WI, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab. 1996;81(5):1736-9.
19. Rosenberg CL, Kim HG, Shows TB, Kronenberg HM, Arnold A. Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors. Oncogene. 1991;6(3):449-53.
20. Hemmer S, Wasenius VM, Haglund C, Zhu Y, Knuutila S, Franssila K, et al. Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol. 2001;158(4):1355-62.
21. Vasef MA, Brynes RK, Sturm M, Bromley C, Robinson RA. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol. 1999;12(4):412-6.
22. Pausova Z, Soliman E, Amizuka N, Janicic N, Konrad EM, Arnold A, et al. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 1996;81(7):2711-8.
23. Padberg BC, Schröder S, Jochum W, Kastendieck H, Roth J, Heitz PU, et al. Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland. Am J Pathol. 1995;147(6):1600-7.
24. Carling T, Correa P, Hessman O, Hedberg J, Skogseid B, Lindberg D, et al. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. J Clin Endocrinol Metab. 1998;83(8):2960-3.
25. Farnebo F, Teh BT, KytöläS, Svensson A, Phelan C, Sandelin K, at al. Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab. 1998;83(8):2627-30.
26. Samander EH, Arnold A. Mutational analysis of the vitamin D receptor does not support its candidacy as a tumor suppressor gene in parathyroid adenomas. J Clin Endocrinol Metab. 2006;91(12):5019-21.
27. Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR, et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab. 2000;85(3):1054-8.
28. Björklund P, Akerström G, Westin G. Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic se-condary hyperparathyroid tumors. J Clin Endocrinol Metab. 2007;92(1):338-44.
29. Björklund P, Lindberg D, Akerström G, Westin G. Stabilizing mutation of CTNNB1/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients. Mol Cancer. 2008;7:53.
30. Fraser, W. Hyperparathyroidism. Lancet. 2009;374:145-58.
31. Pallan S, Khan A. Primary hyperparathyroidism. Can Fam Physician. 2011;57:184-9.
32. Christensen S, Nissen PH, Vestergaard P, Heickendorff L, Brixen K, Mosekilde L. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf). 2008;69(5):713-20.
33. Mackenzie-Feder J, Sirrs S, Anderson D, Sharif J, Khan A. Primary hyperparathyroidism: an overview. Int J Endocrinol. 2011;2011:251410.
34. Yu N, Donnan PT, Murphy MJ, Leese GP. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clinical Endocrinology. 2009;71:485-93.
35. Andrade LD, Marques TF, Diniz ET, Lucena CS, Griz L, Bandeira F. Impact of the use of hydrochlorothiazide in secretion PTH in hypertensive patients. Arq Bras Endocrinol Metab. 2010;54(Supl 5):S491.
36. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94(2):340-50.
37. Pradeep PV, Jayashree B, Mishra A, Mishra SK. Systematic review of primary hyperparathyroidism in India: the past, present and the future trends. Int J Endocrinol. 2011;2011:921814.
38. Gao P, Scheibel S, D'Amour P, John MR, Rao DS, Schmidt-Gayk H, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone (1-84): implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res. 2001;16:605-14.
39. Silverberg SJ, Gao P, Brown I, Logerfo P, Cantor TL, Bilezikian JP. Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:4725-30.
40. Carnevale V, Dionisi S, Nofroni I, Romagnoli E, Paglia F, De Geronimo S, et al. Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem. 2004;50:626-31.
41. Boudou P, Ibrahim F, Cormier C, Chabas A, Sarfati E, Souberbielle JC. Third- or second-generation parathyroid hormone assays: a remaining debate in the diagnosis of primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:6370-2.
42. Bringhurst FR. Circulating forms of parathyroid hormone: peeling back the onion. Clin Chem. 2003;49:1973-5.
43. Bandeira F, Caldas G, Freese E, Griz L, Faria M, Bandeira C. Relationship between vitamin D serum status and clinical manifestations of primary hyperparathyroidism. Endocr Pract. 2002;8:266-70.
44. Suh J, Cronan JJ, Monchik JM. Primary hyperparathyroidism: is there an increased prevalence of renal stone disease? AJR Am J Roentgenol. 2008;191(3):908-11.
45. Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab. 2011;96(8):2377-85.
46. Amaral LMB, Queiroz DC, Marques TF, Mendes M, Bandeira F. Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos. 2012;2012:128352.
47. Marques TF, Vasconcelos R, Diniz E, Rêgo D, Griz L, Bandeira F. Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? Arq Bras Endocrinol Metabol. 2011;55(5):314-7.
48. Khan A, Bilezikian JP. Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ. 2000;163(2):184-7.
49. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab. 2009;94:351-65.
50. Valdemarsson S, Lindergard B, Tibblin S, Bergenfelz A. Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease. J Intern Med. 1998;243:115-22.
51. Roschger P, Dempster DW, Zhou H, Paschalis EP, Silverberg SJ, Shane E, et al. New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. J Bone Miner Res. 2007;22:717-23.
52. Siilin H, Lundgren E, Mallmin H, Mellström D, Ohlsson C, Karlsson M, et al. Prevalence of primary hyperparathyroidism and impact on bone mineral density in elderly men: MrOs Sweden. World J Surg. 2011;35(6):1266-72.
53. Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94(7):2306-12.
54. Khosla S, Melton Jr, Wermers RA, Crowson CS, O'Fallon W, Riggs B. Primay hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14(10):1700-7.
55. Tamura Y, Araki A, Chiba Y, Mori S, Hosoi T, HoriuchiT. Remarkable increase in lumbar spine bone mineral density and amelioration in biochemical markers of bone turnover after parathyroidectomy in elderly patients with primary hyperparathyroidism: a 5-year follow-up study. J Bone Miner Metab. 2007;25:226-31.
56. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;93:3462-70.
57. Rao DS, Philips ER, Divind GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2004;89:5415-22.
58. VanderWalde LH, Liu IL, Haigh PI. Effect of bone mineral density and parathyroidectomy on fracture risk in primary hyperparathyroidism. World J Surg. 2009;33(3):406-11.
59. Cusano N, Wang P, Cremers S, Haney E, Bauer D, Orwoll E, et al. Subclinical hypoparathyroidism: a new variant based upon a cohort from MrOS. J Bone Miner Res. 2011;26(Suppl1):S183.
60. Eriksen E. Primary hyperparathyroidism: lessons from bone histomorphometry. J Bone Miner Res. 2002;17:N95-7.
61. Dempster DW, Muller R, Zhou H, Kohler T, Shane E, Parisien M, et al. Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone. 2007;41:19-24.
62. Charopoulos I, Tournis S, Trovas G, Raptou P, Kaldrymides P, Skarandavos G, et al. Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women. J Clin Endocrinol Metab. 2006;91:1748-53.
63. Joborn C, Hetta J, Johansson H, Rastad J, Agren H, Akerström G, et al. Psychiatric morbidity in primary hyperparathyroidism. World J7 Surg. 1988;12:476-81.
64. Silverberg SJ. Non-classical target organs in primary hyperparathyroidism. J Bone Miner Res. 2002;17(suppl 2):N117-25.
65. Yu N, Donnan PT, Flynn RW, Murphy MJ, Smith D, Rudman A. Increased mortality and morbidity in mild primary hyperparathyroid patients. The parathyroid epidemiology and audit research study (PEARS). Clin Endocrinol. 2010;73:30-4.
66. Coker LH, Rorie K, Cantley L, Kirkland K, Stump D, Burbank N, et al. Primary hyperparathyroidism, cognition, and health-related quality of life. Ann Surg. 2005;242(5):642-50.
67. Walker MD, McMahon DJ, Inabnet WB, Lazar RM, Brown I, Vardy S, et al. Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab. 2009;94(6):1951-8.
68. Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Tørring O, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007;92(5):1687-92.
69. Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007;92(8):3114-21.
70. Conri C, Ducloux G, Lagueny A, Ferrer M, Vital C. Polyneuropathy in type I multiple endocrine syndrome. Presse Med. 1990;19(6):247-50.
71. Eufrazino CSS, Bandeira F, et al. Peripheral polyneuropathy associated with primary hyperparathyroidism. Arq Bras Endocrinol Metab. 2008;52(Suppl.6):976.
72. Moskal W. Severe sensorimotor polyneuropathy in primary hyperparathyroidism. Neurol Neurochir Pol. 1999;33(6):1443-7.
73. Logullo F, Babbini MT, Di Bella P, Provinciali L. Reversible combined cognitive impairment and severe polyneuropathy resulting from primary hyperparathyroidism. Ital J Neurol Sci. 1998;19(2):86-9.
74. Olukoga A. Lessons to be learned: a case study approach. Primary hyperparathyroidism simulating an acute severe polyneuritis. J R Soc Health. 1998;118(2):103-6.
75. Patten BM, Bilezikian JP, Mallette LE, Prince A, Engel WK, Aurbach GD. Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med. 1974;80(2):182-93.
76. Turken SA, Cafferty M, Silverberg SJ, De La Cruz L, Cimino C, Lange DJ, et al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med. 1989;87(5):553-7.
77. Chou FF, Sheen-Chen SM, Leong CP. Neuromuscular recovery after parathyroidectomy in primary hyperparathyroidism. Surgery. 1995;117(1):18-25.
78. Bilezikian JP, Khan A., Potts JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab. 2009;94:335-9.
79. Luboshitzky R, Chertok-Schaham Y, Lavi I, Ishay A. Cardiovascular risk factors in primary hyperparathyroidism. J Endocrinol Invest. 2009;32:317-21.
80. Palmer M, Adami HO, Bergstrom R, Akerstrom G, Ljunghall S. Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979. Surgery. 1987;102:1-7.
81. Ronni-Sivula H. Causes of death in patients previously operated on for primary hyperparathyroidism. Ann Chir Gynaecol. 1985;74:13-8.
82. Hedback G, Tisell LE, Bengtsson BA, Hedman I, Oden A. Premature death in patients operated on for primary hyperparathyroidism. World J Surg. 1990;14:829-36.
83. Letizia C, Ferrari P, Cotesta D, Caliumi C, Cianci R, Cerci S, et al. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J Hum Hypertens. 2005;19(11):901-6.
84. Heyliger A, Tangpricha V, Weber C, Sharma J. Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism. Surgery. 2009;146(6):1042-7.
85. Lind L, Jacobsson S, Palmer M, Lithell H, Wengle B, Ljunghall S. Cardiovascular risk factors in primary hyperparathyroidism: a 15year follow-up of operated and unoperated cases. J Intern Med. 1991;230:29-35.
86. Dalberg K, Brodin LA, Juhlin-Dannfelt A, Farnebo LO. Cardiac function in primary hyperparathyroidism before and after operation. An echocardiographic study. Eur J Surg. 1996;162:171-6.
87. Piovesan A, Molineri N, Casasso F, Emmolo I, Ugliengo G, Cesario F, et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf). 1999;50:321-28.
88. Almqvist EG, Bondeson AG, Bondeson L, Nissborg A, Smedgard P, Svensson SE. Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy. Surgery. 2002;132:1126-32.
89. Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab. 1997;82(1):106-12.
90. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg. 2003;27:216-22.
91. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90(6):3326-30.
92. Smith JC, Page MD, John R, Wheeler MH, Cockcroft JR, Scanlon MF, et al. Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2000;85:3515-9.
93. Walker MD, Fleischer J, Rundek T, McMahon DJ, Homma S, Sacco R, et al. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94(10):3849-56.
94. Ekmekci A, Abaci N, Ozbey NC, Agayev A, Aksakal N, Oflaz H, et al. Endothelial function and endothelial nitric oxide synthase intron 4a/b polymorphism in primary hyperparathyroidism. J Endocrinol Invest. 2009;32:611-6.
95. Lind L, Ridefelt P, Rastad J, Akerstrom G, Ljunghall S. Cytoplasmic calcium regulation and the electrocardiogram in patients with primary hyperparathyroidism. Clin Physiol. 1994;14:103-10.
96. Stefenelli T, Mayr H, Bergler-Klein J, Globits S, Woloszczuk W, Niederle B. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med. 1993;95:197-202.
97. Marcocci C, Cetani F. Primary hyperparathyroidism. N Engl J Med. 2011;365:2389-97.
98. Schiffl H, Lang SM. Hypertension secondary to PHPT: cause or coincidence? Int J Endocrinol. 2011;2011:974647.
99. Walker MD, Fleischer JB, Di Tullio MR, Homma S, Rundek T, Stein EM, et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2010;95(5): 2172-9.
100. Ishay A, Herer P, Luboshitzky R. Effects of successful parathyroidectomy on metabolic cardiovascular risk factors in patients with severe primary hyperparathyroidism. Endocr Pract. 2011;17(4):584-90.
101. Macfarlane DP, Yu N, Donnan PT, Leese GP. Should mild primary hyperparathyroidism be reclassified as insidious: is it time to reconsider? Clin Endocrinol. 2011;75(6):730-7.
102. Yu N, Donnan PT, Leeset GP. A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the parathyroid epidemiology and audit research study (PEARS). Clin Endocrinol. 2011;75:160-76
103. Silverberg SJ, Bilezikian JP. Primary hyperparathyroidism. Endocrinology. 2001;1075-93.
104. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92:3001-5.
105. Silverberg SJ, Bilezikian JP. "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab. 2003;88(11):5348.
106. Kohri k, Takada M, Katoh Y, Kataoka K, Iguchi M, Yachiku Sx, /xetalet al/etal. Parathyroid hormone and electrolytes during long-term treatment with allopurinol and thiazide. Br J Urol. 1987;59(6):503-7.
107. Cusano NE, Wang P, Cremers S, Haney E, Baure D, Orwoll E, et al. Asymptomatic normocalcemic primary hyperparathyroidism: characterization of a new phenotype of normocalcemic primary hyperparathtroidism. J Bone Miner Res. 2011;26(Suppl. 1):S290.
108. Udelsman R, Pasieka JL, Sturgeon C, Young JE, Clark OH. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab. 2009;94:366-72.
109. Mohammadi A, Moloudi F, Ghasemi-rad M. The role of colour Doppler ultrasonography in the preoperative localization of parathyroid adenomas. Endocr J. 2012;59(5):375-82.
110. Bandeira F., Oliveira RI, Griz LH, Caldas G, Bandeira C. Differences in accuracy of TC 99m - Sestamibi scanning between severe and mild forms of primary hyperparathyroidism. J Nucl Med Technol. 2008;36:30-5.
111. Elaraj DM, Spippel RS, Lindsay S, Sansano I, Duh Q, Clark QH, et al. Are additional localization studies and referral indicated for patients with primary hyperparathyroidism who have negative Sestamib scan results? Arch Surg. 2010;145(6):578-81.
112. Chazen JL, Gupta A, Dunning A, Phillps CD. Diagnostic accuracy of 4D-CT for parathyroid adenomas and hyperplasia. Am J Neuroradiol. 2012;33:429-33.
113. Rubin MR, Livolsi VA, Bandeira F, Caldas G, Bilezikian JP. Tc 99m-sestamibi uptake in osteitis fibrosa cystica simulating metastatic bone disease. J Clin Endocrinol Metab. 2001; 86(11):5138-41.
114. Carvalho JRP, Diniz ET, Marques TF, Lima TPM, Galamba L, Bandeira F. PTH measurement in the fine-needle aspirates from cervical nodules in primary hyperparathyroidism. Endocr Rev. 2011;32:P1-251.
115. Silverbeg Sj, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RBx, /xetalet al/etal. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab. 1995;80:729-34.
116. Bollerslev J, Rosen T, Mollerup CL, Nordenstrom J, Baranowski M, Franco C, et al. Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94:2255-61.
117. Silverberg SJ, Bilezikian JP. The diagnosis and management of asymptomatic primary hyperparathyroidism. Nat Clin Pract Endocrinol Metab. 2006;2(9):494-503.
118. Sankaran S, Gamble G, Bolland M, Reid IR, Grey A. Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. J Clin Endocrinol Metab. 2010;95:1653-62.
119. Zanocco K, Heller M, Sturgeon C. Cost-efectiveness of parathyroidectomy for primary hyperparathyroidism. Endocr Pratc. 2011;17(Suppl1):69-74.
120. Stavrakis AI, Ituarte PH, Ko CY, Yeh MW. Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery. 2007;142:887-99.
121. Zanocco K, Sturgeon C. How should age at diagnosis impact treatment strategy in asymptomatic primary hyperparathyroidism? A cost-effectiveness analysis. Surgery. 2008;144:290-8.
122. Allendorf J, DiGorgi M, Spanknebel K, Inabnet W, Chabot J, Logerfo P. 1112 consecutive bilateral neck explorations for primary hyperparathyroidism. World J Surg. 2007;31:2075-80.
123. Udelsman R, Donovan PI, Sokoll LJ. One hundred consecutive minimally invasive parathyroid explorations. Ann Surg. 2000;232:331-9.
124. Agarwal G, Barraclough BH, Reeve TS. Minimally invasive parathyroidectomy using the "focused" lateral approach. II. Surgical technique. Aust N Z J Surg. 2002;72:147-51.
125. Rubello D, Mariani G, Pelizzo MR. Minimally invasive radio-guided parathyroidectomy on a group of 452 primary hyperparathyroid patients: refinement of preoperative imaging and intraoperative procedure. Nuklearmedizin. 2007;46(3):85-92.
126. Melck AL, Armstrong MJ, Yip L, Carty SE. Case-controlled comparison of video-assisted and conventional minimally invasive parathyroidectomy. Am Surg. 2012;78(1):125-32.
127. Dobrinja C, Trevisan G, Liguori G. Minimally invasive video-assisted parathyroidectomy. Initial experience in a General Surgery Department. J Endocrinol Invest. 2009;32(2):130-3.
128. Lombardi CP, Raffaelli M, Traini E, De Crea C, Corsello SM, Bellantone R. Video-assisted minimally invasive parathyroidectomy: benefits and longterm results. World J Surg. 2009;33:2266-81.
129. Bergenfelz A, Kanngiesser V, Zielke A, Nies C, Rothmund M. Conventional bilateral cervical exploration versus open minimally invasive parathyroidectomy under local anaesthesia for primary hyperparathyroidism. Br J Surg. 2005;92(2):190-7.
130. Westerdahl J, Bergenfelz A. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: five-year follow-up of a randomized controlled trial. Ann Surg. 2007;246:976-81.
131. Russell CF, Dolan SJ, Laird JD. Randomized clinical trial comparing scan-directed unilateral versus bilateral cervical exploration for primary hyperparathyroidism due to solitary adenoma. Br J Surg. 2006;93:418-21.
132. Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg. 2002;236(5):543-51.
133. Slepavicius A, Beisa V, Janusonis V, Strupas K. Focused versus conventional parathyroidectomy for primary hyperparathyroidism: a prospective, randomized, blinded trial. Langenbecks Arch Surg. 2008;393(5):659-66.
134. Utiger RD. Treatment of primary hyperparathyroidism. N Engl J Med. 1999;341(17):1301-2.
135. Silverberg SJ, Shane E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341:1249-55.
136. Kaji H, Yamauchi M, Nomura R, Sugimoto T. Improved peripheral cortical bone geometry after surgical treatment of primary hyperparathyroidism in postmenopausal women. J Clin Endocrinol Metab. 2008;93:3045-50.
137. Talpos GB, Bone HG 3rd, Kleerekoper M, Phillips ER, Alam M, Honasoge M, et al. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery. 2000;128(6):1013-20.
138. Silverberg SJ, Locker FG, Bilezikian JP. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81(11):4007-12.
139. Nomura R, Sugimoto T, Tsukamoto T, Yamauchi M, Sowa H, Chen Q, et al. Marked and sustained increase in bone mineral density after parathyroidectomy in patients with primary hyperparathyroidism; a six-year longitudinal study with or without parathyroidectomy in a Japanese population. Clin Endocrinol (Oxf). 2004;60(3):335-42.
140. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab. 1995;80(3):723-8.
141. Parisien M, Cosman F, Mellish RW, Schnitzer M, Nieves J, Silverberg SJ, et al. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res. 1995;10(9):1393-9.
142. Ayturk S, Gursoy A, Bascil Tutuncu N, Ertugrul DT, Guvener Demirag N. Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2006;91(11):4260-3.
143. Guo CY, Thomas WE, al-Dehaimi AW, Assiri AM, Eastell R. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81(10):3487-91.
144. Grey A., Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med. 1996;125(5):360-8.
145. Wilson RJ, Rao S, Ellis B, Kleerekoper M, Parfitt AM. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med. 1988;109(12):959-62.
146. Vestergaard P, Mosekilde L. Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ. 2003;327(7414):530-4.
147. Vestergaard P, Mollerup CL, Frøkjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000;321(7261):598.
148. Prager G, Kalaschek A, Kaczirek K, Passler C, Scheuba C, Sonneck G, et al. Parathyroidectomy improves concentration and retentiveness in patients with primary hyperparathyroidism. Surgery. 2002;132:930-6.
149. Roman SA, Sosa JA, Mayes L, Desmond E, Boudourakis L, Lin R, et al. Parathyroidectomy improves neurocognitive deficits in patients with primary hyperparathyroidism. Surgery. 2005;138:1121-9.
150. Walker MD, Silverberg SJ. Parathyroidectomy in asymptomatic primary hyperparathyroidism: improves "bones" but not "psychic moans". J Clin Endocrinol Metab. 2007;92(5):1613-5.
151. Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroidism. 10-year prospective study. Mayo Clin Proc. 1981;56(8):473-8.
152. Hedback M, Odén S. Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. J Intern Med. 2002;251:476-83.
153. Persson A, Bollerslev J, Rosen T, Mollerup CL, Franco C, Isaksen GA, et al. Effect of surgery on cardiac structure and function in mild primary hyperparathyroidism. Clin Endocrinol (Oxf). 2011;74:174-80.
154. Farahnak P, Ring M, Caidahl K, Farnebo LO, Eriksson MJ, Nilsson IL, et al. Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy. Eur J Endocrinol. 2010;163:461-7.
155. Roman SA, Sosa JA, Pietrzak RH, Snyder PJ, Thomas DC, Udelsman R, et al. The effects of serum calcium and parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism. Ann Surg. 2011;253(1):131-7.
156. Clerici T, Brandle M, Lange J, Doherty GM, Gauger PG. Impact of intraoperative parathyroid hormone monitoring on the prediction of multiglandular parathyroid disease. World J Surg. 2004;28(2):187-92.
157. Ohe MN, Santos RO, Kunii IS, Abrahão M, Cervantes O, Carvalho AB, et al. Utilidade da medida de PTH intra-operatório no tratamento cirúrgico do hiperparatiroidismo primário e secundário: análise de 109 casos. Arq Bras Endocrinol Metab. 2006;50(5):869-75.
158. Barczynski M, Konturek A, Cichon S, Hubalewska-Dydejczyk A, Golkowski F, et al. Intraoperative parathyroid hormone assay improves outcomes of minimally invasive parathyroidectomy mainly in patients with a presumed solitary parathyroid adenoma and missing concordance of preoperative imaging. Clin Endocrinol (Oxf). 2007;66(6):878-85.
159. Hwang RS, Morris LF, Ro K, Park S, Ituarte PH, Hong JC, et al. A selective, Bayesian approach to intraoperative PTH monitoring. Ann Surg. 2010;251(6):1122-6.
160. Bergenfelz A., Jansson SK, Wallin GK, Mårtensson HG, Rasmussen L, Eriksson HL, et al. Impact of modern techniques on short-term outcome after surgery for primary hyperparathyroidism: a multicenter study comprising 2,708 patients. Langenbecks Arch Surg. 2009;394(5):851-60.
161. Miccoli P, Berti P, Materazzi G, Ambrosini CE, Fregoli L, Donatini G. Endoscopic bilateral neck exploration versus quick intraoperative parathormone assay (qPTHa) during endoscopic parathyroidectomy: a prospective randomized trial. Surg Endosc. 2008;22:398-400.
162. Vestergaard P. Current pharmacological options for the management of
163. Bollerslev J, Marcocci C, Sosa M, Nordenström J, Bouillon R, Mosekilde L. Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol. 2011;165):851-64.
164. Peacock M, Bilezikian JP, Klasssen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90(1):135-41.
165. Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab. 2009;94(12):4860-7.
166. Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, et al. Cinacalcet reduces serum calcium concentra tions in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94(8):2766-72.
167. Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey A., Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med. 2000;160:2161-6.
168. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:1174-8.
169. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effect of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res. 2001;16:113-9.
170. Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:581-7.
171. Khan A., Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319-25.